retatrutide mechanism triple agonist gip glp-1 glucagon receptor What GLP‑3 Really Is: Retatrutide Triple‑Receptor Drug Retatrutide: How the Triple Agonist

Proc Natl Acad Sci 97:68746879

A $3,500 value for $147

The 26-week LEAD-6 trial (effect of liraglutide or exenatide added to an ongoing treatment on blood glucose control in subjects with type 2 diabetes) compared once daily liraglutide 1.8 mg to twice daily exenatide 10 g in patients with T2DM inadequately controlled with metformin, a sulfonylurea, or both

Because the connected network was sparse and only weakly looped, formal inconsistency testing was not treated as decisive, and SUCRA/rank probabilities are interpreted as exploratory summaries rather than confirmatory treatment ordering

None of these constitute addiction

Kim S, Moon M, Park S